Skip to main content
Equibles
LAB logo

LAB · Standard Biotools Inc. · Metrics

Track LAB — free

Use LAB with AI

Ask our own analyst here, or connect this data to the AI you already use.

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

Claude ChatGPT Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$0.74 +0.05 (+7.17%)
Rebalance outlook locked
Market Cap
$281.44M
Shares
392.58M

LAB metrics

70 of 115 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$0.69
Market cap
$281.44M

Price action

20 metrics
Price change (1W)
+6.8%
Price change (30D)
-13.2%
Price change (3M)
-40.4%
Price change (6M)
-30.8%
Price change (YTD)
-46.4%
Price change (1Y)
-46.9%
Trailing year
Price change (5Y)
-90.5%
52-week high
$1.68
52-week low
$0.64
Change from 52-week high
-59.2%
Change from 52-week low
+6.8%
Annualized volatility
69.4%
Annualized volatility (3M)
91.5%
Beta
1.2
RSI (14D)
43.7
Price vs SMA 50
-12.5%
Price vs SMA 200
-35.4%
Avg volume (3M)
3.21M
Relative volume
0.6
Average dollar volume
$2.57M

Company

3 metrics
Sector
Healthcare
Industry
Medical Devices
Shares outstanding
392.58M

Valuation

12 metrics
P / E (TTM)
3.1
Trailing earnings · reciprocal yield 32.1%
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
3.2×
reciprocal yield 31.4%
P / book
0.5
reciprocal yield 200.6%
FCF yield
-30.7%
TTM · current market cap
Buyback yield
0.0%
P / FCF
—
P / operating cash flow
—
Earnings yield
31.6%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
2.8×
reciprocal yield 35.7%
EV / revenue historical average (5Y)
2.8×
reciprocal yield 35.7%
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
0.0%
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2025-08-11

Profitability

9 metrics
Gross margin
50.5%
Operating margin
-112.8%
Trailing 12 months
Net margin
100.4%
Gross profit (TTM)
$42.71M
Operating profit (TTM)
−$95.47M
Net income (TTM)
$84.91M
Trailing 12 months
Diluted EPS (TTM)
$0.22
FCF margin
-97.6%
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$1.44

Growth

11 metrics
Revenue growth YoY
-7.6%
Year over year
Net income growth YoY
—
Revenue (TTM)
$84.60M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+2.7%
Year over year · more shares
Revenue CAGR (3Y)
-4.5%
Revenue CAGR (5Y)
-9.2%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
15.7%
Return on assets
13.5%
Debt / equity
—
Current ratio
9.1
EBITDA (TTM)
−$89.97M
Free cash flow (TTM)
−$82.58M
Quick ratio
8.8
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
$270.03M
Total assets
$627.22M
Total debt
—

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$80.30M
Capital expenditures (TTM)
$2.28M
R&D (TTM)
$18.42M
SG&A (TTM)
$86.93M
Stock compensation (TTM)
$27.09M
R&D / revenue
21.8%
Stock compensation / revenue
32.0%

Ownership (13F)

3 metrics
13F filers
144
13F filer change QoQ
-12
Institutional ownership
75.5%

Short interest

3 metrics
Short interest
0.6%
Latest settlement · 2.2 days to cover
Days to cover
2.2d
Short-squeeze score
32 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
—
Key facts CIK 1162194 CUSIP 34385P108 13F (30d) 105 filings 105 filers Visit website Investor relations